While the NIH SLA is recommended for transferring most materials, NIH guidelines recognized that if materials were patented, additional terms may be needed in an MTA to protect the rights of the providing institution in the materials. The UBMTA takes into account that the transferred material may be subject to patent protection and can be used for patented as well as unpatented materials. If both institutions are signatories to the UBMTA, one simply executes the implementing letter for each transfer. Non-signatories may sign the UBMTA Master Agreement and then use the Implementing Letter as a UBMTA signatory. Alternatively, non-signatories can use the AUTM MTA Templates, which are stand-alone contracts based on the UBMTA.
UBMTA Master Agreement
UBMTA Implementing Letter
AUTM agreed with NIH that, as a matter of convenience, AUTM will serve as the repository for the signed UBMTA Master Agreements from those institutions wishing to use the UBMTA for some or all of their exchanges of biological materials. AUTM will archive the signed Master Agreements in the original form received and will periodically post a listing including: the name of the institution, the name and title of the official signatory and the date the Master Agreement was signed. If any institution subsequently decides to withdraw its acceptance of the Master Agreement, AUTM will add the date the institution withdrew its approval. AUTM makes no representations as to the accuracy of the information transcribed from the Master Agreements for posting to this list or as to the actual authority of the signature. Each institution relying on the AUTM listing does so at its own risk.
To become a UBMTA Signatory, download the UBMTA Master Agreement, then print, complete, sign and email to AUTM Director of Operations, Stephanie Pearson at [email protected], or mail it to AUTM at: 712 H Street NE, Ste. 1611, Washington, DC 20002
Read UBMTA Federal Register Information
Return to MTA Toolkit
Master UBMTA Agreement Signatories